Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage Occlusion (INTEGRAL)

NCT07840365 is registered in ClinicalTrials.gov with Texas Cardiac Arrhythmia Research Foundation as lead sponsor.

NCT NCT07840365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07840365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage Occlusion (INTEGRAL)
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Phase
Phase 3
Overall status
Recruiting
Start date
September 1, 2026
Completion date
September 30, 2029
Enrollment
234 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation (af)